INTRODUCTION: Local delivery of adriamycin (ADR) via biodegradable polymers has been shown to improve survival in rats challenged intracranially with 9L gliosarcoma. Likewise, local delivery of interleukin-2 (IL-2) has been shown to extend survival in experimental brain tumor models. In the current study, we hypothesized that local delivery of ADR and IL-2 might act synergistically against experimental intracranial glioma. METHODS: Polyanhydride polymers (PCPP-SA) containing 5% ADR by weight were prepared using the mix-melt method. IL-2 polymer microspheres (IL-2 MS) were produced via the complex coacervation of gelatin and chondroitin sulfate in the presence of IL-2. Sixty male Fisher 344 rats received an intracranial challenge with a lethal dose of 9L gliosarcoma cells. In addition, a group of rats were injected with either IL-2 MS or empty microspheres. Five days later they received ADR or blank polymer. There were a total of four treatment groups: (1) empty microspheres, blank polymer; (2) empty microspheres, ADR polymer; (3) IL-2 MS, blank polymer; and (4) IL-2 MS, ADR polymer. RESULTS: Compared to control animals treated with empty microspheres and blank polymer, animals receiving empty microspheres and ADR polymer (P < 0.0004), IL-2 MS and blank polymer (P < 0.0005), and IL-2 MS combined with ADR polymer (P < 0.0000002) all showed statistically significant improvement in survival. In addition, animals receiving the IL-2/ADR combination had significantly extended survival compared to either ADR or IL-2 alone (P < 0.000003 and P < 0.0004, respectively). CONCLUSIONS: Both ADR and IL-2, when delivered locally, are effective monotherapeutic agents against experimental intracranial gliosarcoma. The combination ADR and IL-2 therapy is more effective than either agent alone.
INTRODUCTION: Local delivery of adriamycin (ADR) via biodegradable polymers has been shown to improve survival in rats challenged intracranially with 9L gliosarcoma. Likewise, local delivery of interleukin-2 (IL-2) has been shown to extend survival in experimental brain tumor models. In the current study, we hypothesized that local delivery of ADR and IL-2 might act synergistically against experimental intracranial glioma. METHODS:Polyanhydride polymers (PCPP-SA) containing 5% ADR by weight were prepared using the mix-melt method. IL-2polymer microspheres (IL-2 MS) were produced via the complex coacervation of gelatin and chondroitin sulfate in the presence of IL-2. Sixty male Fisher 344 rats received an intracranial challenge with a lethal dose of 9L gliosarcoma cells. In addition, a group of rats were injected with either IL-2 MS or empty microspheres. Five days later they received ADR or blank polymer. There were a total of four treatment groups: (1) empty microspheres, blank polymer; (2) empty microspheres, ADR polymer; (3) IL-2 MS, blank polymer; and (4) IL-2 MS, ADR polymer. RESULTS: Compared to control animals treated with empty microspheres and blank polymer, animals receiving empty microspheres and ADR polymer (P < 0.0004), IL-2 MS and blank polymer (P < 0.0005), and IL-2 MS combined with ADR polymer (P < 0.0000002) all showed statistically significant improvement in survival. In addition, animals receiving the IL-2/ADR combination had significantly extended survival compared to either ADR or IL-2 alone (P < 0.000003 and P < 0.0004, respectively). CONCLUSIONS: Both ADR and IL-2, when delivered locally, are effective monotherapeutic agents against experimental intracranial gliosarcoma. The combination ADR and IL-2 therapy is more effective than either agent alone.
Authors: S Valtonen; U Timonen; P Toivanen; H Kalimo; L Kivipelto; O Heiskanen; G Unsgaard; T Kuurne Journal: Neurosurgery Date: 1997-07 Impact factor: 4.654
Authors: J Hanes; A Sills; Z Zhao; K W Suh; B Tyler; F DiMeco; D J Brat; M A Choti; K W Leong; D M Pardoll; H Brem Journal: Pharm Res Date: 2001-07 Impact factor: 4.200
Authors: A Nigam; R F Yacavone; M L Zahurak; C M Johns; D M Pardoll; S Piantadosi; H I Levitsky; W G Nelson Journal: Int J Oncol Date: 1998-01 Impact factor: 5.650
Authors: Peter Hau; Klaus Fabel; Ulrike Baumgart; Petra Rümmele; Oliver Grauer; Annekatrin Bock; Christopher Dietmaier; Wolfgang Dietmaier; Jörg Dietrich; Christine Dudel; Franz Hübner; Tanya Jauch; Elisabeth Drechsel; Ingo Kleiter; Cäcile Wismeth; Anton Zellner; Alexander Brawanski; Andreas Steinbrecher; Jörg Marienhagen; Ulrich Bogdahn Journal: Cancer Date: 2004-03-15 Impact factor: 6.860
Authors: A M Sonabend; I V Ulasov; Y Han; C E Rolle; S Nandi; D Cao; M A Tyler; M S Lesniak Journal: Cancer Gene Ther Date: 2008-11-14 Impact factor: 5.987